Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Approach to the treatment of multiple myeloma: a clash of philosophies.

Literature DB >> 21791430

Approach to the treatment of multiple myeloma: a clash of philosophies.

S Vincent Rajkumar¹, Gösta Gahrton, P Leif Bergsagel.

Abstract

In this Perspective, we summarize some of the most contentious issues surrounding diagnosis and treatment of myeloma. We outline how a fundamental clash of philosophies, cure versus control, may be at the heart of many of the controversies. From the very definition of the disease to risk stratification to the validity of current clinical trial endpoints, we highlight the major areas of debate and provide alternative viewpoints that have implications for trial design and interpretation, as well as clinical practice.

Entities: Disease

Mesh：

Substances：

Year: 2011 PMID： 21791430 PMCID： PMC3179390 DOI： 10.1182/blood-2011-06-297853

Source DB: PubMed Journal: Blood ISSN： 0006-4971 Impact factor: 22.113

50 in total

Review 1. Overall survival as the outcome for randomized clinical trials with effective subsequent therapies.

Authors: Edward L Korn; Boris Freidlin; Jeffrey S Abrams
Journal: J Clin Oncol Date: 2011-05-09 Impact factor: 44.544

2. Reflections on medical oncology: an appeal for better clinical trials and improved reporting of their results.

Authors: I Tannock; K Murphy
Journal: J Clin Oncol Date: 1983-01 Impact factor: 44.544

3. Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients.

Authors: Francesca Gay; Alessandra Larocca; Pierre Wijermans; Federica Cavallo; Davide Rossi; Ron Schaafsma; Mariella Genuardi; Alessandra Romano; Anna Marina Liberati; Agostina Siniscalchi; Maria T Petrucci; Chiara Nozzoli; Francesca Patriarca; Massimo Offidani; Roberto Ria; Paola Omedè; Benedetto Bruno; Roberto Passera; Pellegrino Musto; Mario Boccadoro; Pieter Sonneveld; Antonio Palumbo
Journal: Blood Date: 2011-01-12 Impact factor: 22.113

4. Antitumor activity of thalidomide in refractory multiple myeloma.

Authors: S Singhal; J Mehta; R Desikan; D Ayers; P Roberson; P Eddlemon; N Munshi; E Anaissie; C Wilson; M Dhodapkar; J Zeddis; B Barlogie
Journal: N Engl J Med Date: 1999-11-18 Impact factor: 91.245

Review 5. Treatment of multiple myeloma.

Authors: S Vincent Rajkumar
Journal: Nat Rev Clin Oncol Date: 2011-04-26 Impact factor: 66.675

6. Molecular remission after myeloablative allogeneic stem cell transplantation predicts a better relapse-free survival in patients with multiple myeloma.

Authors: Paolo Corradini; Michele Cavo; Henk Lokhorst; Giovanni Martinelli; Carolina Terragna; Ignazio Majolino; Pinuccia Valagussa; Mario Boccadoro; Diana Samson; Andrea Bacigalupo; Nigel Russell; Vittorio Montefusco; Claudia Voena; Gosta Gahrton
Journal: Blood Date: 2003-05-08 Impact factor: 22.113

7. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma.

Authors: J Anthony Child; Gareth J Morgan; Faith E Davies; Roger G Owen; Susan E Bell; Kim Hawkins; Julia Brown; Mark T Drayson; Peter J Selby
Journal: N Engl J Med Date: 2003-05-08 Impact factor: 91.245

8. Prognostic factors in allogeneic bone marrow transplantation for multiple myeloma.

Authors: G Gahrton; S Tura; P Ljungman; J Bladé; L Brandt; M Cavo; T Façon; A Gratwohl; A Hagenbeek; P Jacobs
Journal: J Clin Oncol Date: 1995-06 Impact factor: 44.544

9. Clinical course of patients with relapsed multiple myeloma.

Authors: Shaji K Kumar; Terry M Therneau; Morie A Gertz; Martha Q Lacy; Angela Dispenzieri; S Vincent Rajkumar; Rafael Fonseca; Thomas E Witzig; John A Lust; Dirk R Larson; Robert A Kyle; Philip R Greipp
Journal: Mayo Clin Proc Date: 2004-07 Impact factor: 7.616

10. Single versus double autologous stem-cell transplantation for multiple myeloma.

Authors: Michel Attal; Jean-Luc Harousseau; Thierry Facon; François Guilhot; Chantal Doyen; Jean-Gabriel Fuzibet; Mathieu Monconduit; Cyrille Hulin; Denis Caillot; Reda Bouabdallah; Laurent Voillat; Jean-Jacques Sotto; Bernard Grosbois; Regis Bataille
Journal: N Engl J Med Date: 2003-12-25 Impact factor: 91.245

50 in total

1. Haematological cancer: Lenalidomide maintenance--perils of a premature denouement.

Authors: S Vincent Rajkumar
Journal: Nat Rev Clin Oncol Date: 2012-06-05 Impact factor: 66.675

2. Design Issues in Randomized Clinical Trials of Maintenance Therapies.

Authors: Boris Freidlin; Richard F Little; Edward L Korn
Journal: J Natl Cancer Inst Date: 2015-08-18 Impact factor: 13.506

Review 3. Update on risk stratification and treatment of newly diagnosed multiple myeloma.

Authors: Prashant Kapoor; S Vincent Rajkumar
Journal: Int J Hematol Date: 2011-10-18 Impact factor: 2.490

Review 4. First line vs delayed transplantation in myeloma: Certainties and controversies.

Authors: Annamaria Brioli
Journal: World J Transplant Date: 2016-06-24

5. Multiple myeloma: 2018 update on diagnosis, risk‐stratification, and management

Authors:
Journal: Am J Hematol Date: 2018-08-16 Impact factor: 10.047

6. Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival.

Authors: S Ferrero; M Ladetto; D Drandi; F Cavallo; E Genuardi; M Urbano; S Caltagirone; M Grasso; F Rossini; T Guglielmelli; C Cangialosi; A M Liberati; V Callea; T Carovita; C Crippa; L De Rosa; F Pisani; A P Falcone; P Pregno; S Oliva; C Terragna; P Musto; R Passera; M Boccadoro; A Palumbo
Journal: Leukemia Date: 2014-07-16 Impact factor: 11.528